Greatbatch to establish R&D centre in Singapore

SINGAPORE – Greatbatch, Inc. has recently announced plans to establish an Active Implantable Medical Device (AIMD) Research and Development Centre in Singapore.

The establishment of the centre is a continuation of Greatbatch’s medical device strategy and the first step of its strategy to engage in emerging healthcare markets in the Asia Pacific.

The Greatbatch Singapore AIMD R&D Centre is set develop cost-efficient active implantable medical devices and capitalise on emerging market business opportunities, using “frugal innovation” strategies. The centre will focus on the design and development of active implantable medical devices to serve the Cardiovascular and Neuromodulation markets, two of Greatbatch’s core markets.

To serve the Cardiovascular market, the company has identified needs in Interventional Procedures, Atrial Fibrillation ablation, MRI Conditional Systems, as well as targeting health conditions related to Cardiovascular Disease with therapies for Obesity and Obstructive Sleep Apnea. To serve the Neuromodulation market, the company is currently developing a Spinal Cord Stimulator called Algostim, which will treat chronic pain in the trunk and limbs.

“The devices that the Greatbatch Singapore AIMD R&D Centre will design and develop are to be tailored to the unique requirements that exist in emerging markets without sacrificing physician and patient benefits,” said Daniel Kaiser, PhD., Chief Technology Officer of Greatbatch. “In order to develop such complex systems we’ll focus on world class talent with the capabilities to bring these solutions through the development and regulatory stages to serve Asia Pacific and broader worldwide healthcare markets.”

Footwear